Granahan Investment Management LLC Purchases 14,951 Shares of Repligen Corporation $RGEN

Granahan Investment Management LLC boosted its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 20.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,953 shares of the biotechnology company’s stock after buying an additional 14,951 shares during the period. Granahan Investment Management LLC’s holdings in Repligen were worth $10,245,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in shares of Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after buying an additional 1,091,683 shares in the last quarter. United Capital Financial Advisors LLC acquired a new stake in shares of Repligen during the 3rd quarter valued at about $368,387,000. Opti Capital Management LP bought a new stake in Repligen in the fourth quarter valued at about $2,399,209,000. Invesco Ltd. increased its stake in Repligen by 43.9% in the fourth quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock valued at $205,880,000 after acquiring an additional 383,399 shares during the period. Finally, Wasatch Advisors LP acquired a new position in Repligen in the first quarter worth about $146,513,000. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.60% of the stock is currently owned by corporate insiders.

Repligen Stock Down 4.1%

NASDAQ RGEN opened at $131.96 on Friday. The stock’s 50 day simple moving average is $131.68 and its 200 day simple moving average is $132.60. Repligen Corporation has a one year low of $100.99 and a one year high of $175.77. The firm has a market cap of $7.44 billion, a PE ratio of 146.62, a price-to-earnings-growth ratio of 2.65 and a beta of 1.06. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business’s revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Wolfe Research started coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 14th. HSBC cut their target price on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, Evercore reiterated an “outperform” rating and issued a $160.00 price target on shares of Repligen in a research report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $165.36.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.